KR20140036257A - 다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법 - Google Patents
다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법 Download PDFInfo
- Publication number
- KR20140036257A KR20140036257A KR1020137034196A KR20137034196A KR20140036257A KR 20140036257 A KR20140036257 A KR 20140036257A KR 1020137034196 A KR1020137034196 A KR 1020137034196A KR 20137034196 A KR20137034196 A KR 20137034196A KR 20140036257 A KR20140036257 A KR 20140036257A
- Authority
- KR
- South Korea
- Prior art keywords
- subject
- fumarate
- reduced
- years
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 71
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 35
- 102000006386 Myelin Proteins Human genes 0.000 title claims abstract description 17
- 108010083674 Myelin Proteins Proteins 0.000 title claims abstract description 17
- 210000005012 myelin Anatomy 0.000 title claims abstract description 17
- 230000001965 increasing effect Effects 0.000 title claims abstract description 6
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims abstract description 144
- 229960004419 dimethyl fumarate Drugs 0.000 claims abstract description 143
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 87
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 84
- 230000003902 lesion Effects 0.000 claims abstract description 63
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims abstract description 61
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims abstract description 61
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 208000035475 disorder Diseases 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims description 124
- 239000000902 placebo Substances 0.000 claims description 67
- 229940068196 placebo Drugs 0.000 claims description 67
- 230000009467 reduction Effects 0.000 claims description 48
- 230000008859 change Effects 0.000 claims description 21
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000002250 progressing effect Effects 0.000 claims 1
- 229940005650 monomethyl fumarate Drugs 0.000 abstract description 11
- 229910052688 Gadolinium Inorganic materials 0.000 abstract description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 abstract description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 17
- 108010072051 Glatiramer Acetate Proteins 0.000 description 16
- 229960003776 glatiramer acetate Drugs 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 229940121164 dimethyl fumarate 240 mg Drugs 0.000 description 9
- 238000002595 magnetic resonance imaging Methods 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- -1 hydroxypropyl Chemical group 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 6
- 208000017547 Ectodermal dysplasia-syndactyly syndrome Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000016192 Demyelinating disease Diseases 0.000 description 5
- 206010012305 Demyelination Diseases 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000003050 axon Anatomy 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005415 magnetization Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- 208000035657 Abasia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- OEIQOKPNLCRCFM-YBFXNURJSA-N 1-[(E)-(1,3-benzothiazol-2-ylhydrazinylidene)methyl]naphthalen-2-ol Chemical compound Oc1ccc2ccccc2c1\C=N\N=c1\[nH]c2ccccc2s1 OEIQOKPNLCRCFM-YBFXNURJSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 1
- 101001013647 Mus musculus Methionine synthase Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490572P | 2011-05-26 | 2011-05-26 | |
| US61/490,572 | 2011-05-26 | ||
| US201261625624P | 2012-04-17 | 2012-04-17 | |
| US61/625,624 | 2012-04-17 | ||
| PCT/US2012/039721 WO2012162669A1 (en) | 2011-05-26 | 2012-05-25 | Methods of treating multiple sclerosis and preserving and/or increasing myelin content |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140036257A true KR20140036257A (ko) | 2014-03-25 |
Family
ID=47217796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137034196A Withdrawn KR20140036257A (ko) | 2011-05-26 | 2012-05-25 | 다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140163100A1 (enExample) |
| EP (1) | EP2713724A4 (enExample) |
| JP (1) | JP2014515373A (enExample) |
| KR (1) | KR20140036257A (enExample) |
| CN (1) | CN103732062A (enExample) |
| AU (1) | AU2012258558A1 (enExample) |
| BR (1) | BR112013030169A2 (enExample) |
| CA (1) | CA2836480A1 (enExample) |
| CL (1) | CL2013003358A1 (enExample) |
| CO (1) | CO6811862A2 (enExample) |
| EA (1) | EA201391578A1 (enExample) |
| EC (1) | ECSP13013117A (enExample) |
| IL (1) | IL229448A0 (enExample) |
| MX (1) | MX2013013781A (enExample) |
| PE (1) | PE20141316A1 (enExample) |
| PH (1) | PH12013502443A1 (enExample) |
| SG (1) | SG195049A1 (enExample) |
| WO (1) | WO2012162669A1 (enExample) |
| ZA (1) | ZA201308681B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023241A1 (en) | 2003-09-09 | 2005-03-17 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| DK1799196T3 (en) | 2004-10-08 | 2016-08-15 | Forward Pharma As | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| EP2334378B1 (en) | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| US9422226B2 (en) | 2011-06-08 | 2016-08-23 | Biogen Ma Inc. | Process for preparing high purity and crystalline dimethyl fumarate |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| US20140057918A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| AR094277A1 (es) | 2012-12-21 | 2015-07-22 | Biogen Idec Inc | Derivados de fumarato sustituidos con deuterio |
| PT2970101T (pt) | 2013-03-14 | 2018-10-04 | Alkermes Pharma Ireland Ltd | Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| CN103724198A (zh) * | 2013-11-28 | 2014-04-16 | 镇江圣安医药有限公司 | 富马酸二甲酯的新型衍生物及其应用 |
| EP3110793B1 (en) | 2014-02-24 | 2019-08-21 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| WO2015130998A1 (en) | 2014-02-28 | 2015-09-03 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| EP3212626B1 (en) * | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| UA122064C2 (uk) | 2014-12-11 | 2020-09-10 | Актеліон Фармасьютікалз Лтд | Схема дозування для селективного агоніста рецептора s1p1 |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| CN101056624A (zh) * | 2004-10-08 | 2007-10-17 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
| WO2007042034A1 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| LT2653873T (lt) * | 2007-02-08 | 2022-10-10 | Biogen Ma Inc. | Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti |
| US20100130607A1 (en) * | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
| EP2334378B1 (en) * | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
-
2012
- 2012-05-25 SG SG2013085667A patent/SG195049A1/en unknown
- 2012-05-25 US US14/119,373 patent/US20140163100A1/en not_active Abandoned
- 2012-05-25 EA EA201391578A patent/EA201391578A1/ru unknown
- 2012-05-25 CA CA2836480A patent/CA2836480A1/en not_active Abandoned
- 2012-05-25 EP EP12789291.7A patent/EP2713724A4/en not_active Withdrawn
- 2012-05-25 AU AU2012258558A patent/AU2012258558A1/en not_active Abandoned
- 2012-05-25 CN CN201280036988.6A patent/CN103732062A/zh active Pending
- 2012-05-25 JP JP2014512168A patent/JP2014515373A/ja active Pending
- 2012-05-25 KR KR1020137034196A patent/KR20140036257A/ko not_active Withdrawn
- 2012-05-25 WO PCT/US2012/039721 patent/WO2012162669A1/en not_active Ceased
- 2012-05-25 PE PE2013002710A patent/PE20141316A1/es not_active Application Discontinuation
- 2012-05-25 MX MX2013013781A patent/MX2013013781A/es unknown
- 2012-05-25 BR BR112013030169A patent/BR112013030169A2/pt not_active IP Right Cessation
- 2012-05-25 PH PH1/2013/502443A patent/PH12013502443A1/en unknown
-
2013
- 2013-11-14 IL IL229448A patent/IL229448A0/en unknown
- 2013-11-19 ZA ZA2013/08681A patent/ZA201308681B/en unknown
- 2013-11-22 CL CL2013003358A patent/CL2013003358A1/es unknown
- 2013-11-26 CO CO13277997A patent/CO6811862A2/es not_active Application Discontinuation
- 2013-12-26 EC ECSP13013117 patent/ECSP13013117A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391578A1 (ru) | 2014-05-30 |
| ZA201308681B (en) | 2017-11-29 |
| WO2012162669A1 (en) | 2012-11-29 |
| AU2012258558A1 (en) | 2013-05-02 |
| MX2013013781A (es) | 2014-01-08 |
| IL229448A0 (en) | 2014-01-30 |
| SG195049A1 (en) | 2013-12-30 |
| CL2013003358A1 (es) | 2014-08-01 |
| US20140163100A1 (en) | 2014-06-12 |
| EP2713724A1 (en) | 2014-04-09 |
| CN103732062A (zh) | 2014-04-16 |
| EP2713724A4 (en) | 2015-03-11 |
| PH12013502443A1 (en) | 2019-03-22 |
| ECSP13013117A (es) | 2014-06-30 |
| JP2014515373A (ja) | 2014-06-30 |
| BR112013030169A2 (pt) | 2016-08-09 |
| CO6811862A2 (es) | 2013-12-16 |
| PE20141316A1 (es) | 2014-10-01 |
| CA2836480A1 (en) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20140036257A (ko) | 다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법 | |
| EP1001760B1 (en) | Composition for controlling mood disorders in healthy individuals | |
| KR102547164B1 (ko) | 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 | |
| JP6837486B2 (ja) | 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法 | |
| RS51961B (sr) | Primena flibanserina za lečenje poremećaja seksualne želje u premenopauzi | |
| AU2018337933A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
| EP3964210A1 (en) | Methods and compositions for treatment of alzheimer's disease | |
| US20170312265A1 (en) | Method for improving interstitial flow | |
| KR20200026118A (ko) | 헬리코박터 파일로리 제균용 조성물 | |
| JP7524167B2 (ja) | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 | |
| EA001325B1 (ru) | Способы лечения и профилактики интерстициального цистита | |
| KR101887561B1 (ko) | 간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물 | |
| KR100692235B1 (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
| WO2023202989A1 (en) | Treatment of frontal fibrosing alopecia | |
| SE1350211A1 (sv) | Metoder och kompositioner för behandling av cancermetastaser | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| CN1135180A (zh) | 盘昔洛维治疗带状疱疹后神经痛的应用 | |
| US4517309A (en) | Method for the treatment of calcifying pancreatitis | |
| KR102902972B1 (ko) | Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물 | |
| JP2014231518A (ja) | 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用 | |
| EP4353234A1 (en) | Use of pyrrolopyrimidine compound | |
| JP5707137B2 (ja) | レバミピドの骨粗鬆症治療用途 | |
| HK40094581A (en) | Treatment of alzheimer's disease in a particular patient population | |
| TWI418347B (zh) | 治療疱疹病毒感染的方法 | |
| MXPA97001528A (en) | Derivatives of 1, 1, 2, - trifenilbut-1-eno to treat alzhei's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20131223 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |